<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649064</url>
  </required_header>
  <id_info>
    <org_study_id>A1281120</org_study_id>
    <nct_id>NCT00649064</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs</brief_title>
  <official_title>A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if differences exist in outcome in patients with
      schizophrenia or schizoaffective disorder who were switched from other antipsychotics to
      ziprasidone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Brief Psychiatric Rating Scale (BPRS) total score</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Weeks 1, 2, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in prolactin and lipid levels</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Positive and Negative Symptom Scale (PANSS), including PANSS total scores and PANSS positive, PANSS negative, and PANSS general subscale scores</measure>
    <time_frame>Baseline and Weeks 1, 2, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impressions-Severity (CGI-S) scale scores</measure>
    <time_frame>Baseline and Weeks 1, 2, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions-Improvement (CGI-I) scale scores</measure>
    <time_frame>Baseline (using historical data) and Weeks 1, 2, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in movement disorder rating scales, including Barnes Akathisia Scale (BAS) and Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>Baseline and Weeks 1, 2, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Montgomery Asberg Depression Rating Scale (MADRS) scores</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.</description>
    <arm_group_label>Ziprasidone</arm_group_label>
    <other_name>Geodon, Zeldox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder

          -  Outpatients for at least 3 months on treatment with sulpiride, olanzapine, quetiapine,
             or risperidone and at least a partial beneficial response to typical antipsychotic
             treatment including for the current episode

          -  Partial improvement in symptoms that justified a switch to ziprasidone

        Exclusion Criteria:

          -  Diagnosis of major depression or occurrence of moderate depressive symptoms

          -  Resistance to conventional antipsychotic drugs

          -  Treatment with other drugs such as antiseizure medications, antipsychotics,
             antidepressants, or mood stabilizing agents that might interfere with the assessement
             of the efficacy of ziprasidone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281120&amp;StudyName=A%20study%20of%20the%20effects%20of%20ziprasidone%20for%20the%20treatment%20of%20schizophrenia%20or%20schizoaffective%20disorder%20in%20patients%20who%20were%20switched%20fro</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>April 7, 2008</last_update_submitted>
  <last_update_submitted_qc>April 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

